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Skeletal muscle is a remarkably plastic tissue. One 
of the best examples is the ability of muscle to adapt to 
the stress of regular endurance exercise by increasing 
mitochondrial content. Regular exercise is also one of the 
most effective therapies in minimising muscle atrophy 
due to disease. Understanding the molecular regulation 
of these processes has only emerged in the past 15 years. 
Key regulators in these processes are the transcriptional 
co-activators, peroxisome proliferator-activated receptor 
(PPAR)-g coactivator-1a and -1β (PGC-1a and PGC-1β, 
respectively). These transcriptional co-activators are 
known to positively regulate mitochondrial content and 
attenuate muscle atrophy pathways (1). PGC-1a and 
PGC-1β regulate mitochondrial content and function 
by the activation of transcription factors including the 
nuclear respiratory factors 1 and 2 (NRF-1 and NRF-2), 
peroxisome proliferator-activated receptor-a (PPARa) 
and estrogen-related receptor-a (ERRa) (1) (Fig. 1). These 
transcription factors transcribe genes that encode proteins 
important for oxidative enzymes, mitochondrial fusion 
and mitochondrial DNA (mtDNA) transcription, such as 
cytochrome oxidase (COX), mitofusins-1 (Mfn1) and -2 
(Mfn2) and mitochondrial transcription factor A (Tfam), 
respectively.
Exercise Increases Mitochondrial Biogenesis 
Endurance exercise potently stimulates increases in 
skeletal muscle mitochondrial volume; the increased 
mitochondrial biogenesis following exercise training is 
thought to be largely attributed to the cumulative effects 
of each acute bout of exercise (2). Key steps in the exercise-
induced mitochondrial biogenesis pathway in skeletal 
muscle following acute exercise involve p38 MAPK 
phosphorylating and activating transcription factor-2 
(ATF-2), allowing the latter to bind to the cAMP-response 
element-binding protein (CREB) site on the PGC-1a 
promoter and induce PGC-1a gene expression (3). Several 
hours following acute exercise, the expression of the 
skeletal muscle genes encoding PGC-1a, NRF-1, NRF-2 
and Tfam is increased in each case, as also occurs for genes 
encoding NRF-1 and -2, DNA-binding proteins which are 
also involved in coordinating the exercise training response 
(3,4). Acute exercise also activates AMP-activated protein 
kinase (AMPK) (4), which is known to phosphorylate and 
activate PGC-1a (2). Additional regulation by PGC-1 also 
appears to involve its subcellular localisation. In skeletal 
muscle under resting conditions, most PGC-1a protein 
is localised in the cytosol; however, following endurance 
exercise nuclear PGC-1a protein content increases, 
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Fig. 1. A schematic example of several key 
factors that contribute to the exercise-induced 
increase in mitochondrial biogenesis and 
function.
The exercise-induced increase in cytosolic Ca2+, 
AMP, reactive oxygen species (ROS) and possibly 
NAD+ activate several signaling proteins, such 
as p38 MAPK, which phosphorylates and 
activates transcription factor-2 (ATF-2) resulting 
in an increase in PGC-1a gene expression; 
there are also increases in AMPK and SIRT-1 
that phosphorylate and deacetylate PGC-1a, 
respectively, resulting in an increase in PGC-
1a activity. PGC-1a increases the transcription 
and the activation of NRF-1, NRF-2, PPARa 
and ERRa, which are transcription factors that 
transcribe genes such as COX2, COX4, Mfn1, 
Mfn2 and Tfam; each representing a target that 
controls cellular respiration, mitochondrial 
fusion and mtDNA transcription.
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probably by translocation from the cytosol (2,5). Recent 
evidence also suggests that following endurance exercise 
there is a translocation of PGC-1a to the mitochondria 
for co-activation of Tfam (2). Further post-translational 
modification of PGC-1a can be achieved following its 
deacetylation by sirtuin-1 (SIRT-1), which is activated by 
increased NAD+ levels (2) (Fig. 1).
Regulators of Exercise-induced Mitochondrial Biogenesis 
During exercise there is an increase in several molecular 
‘stress’ signals in skeletal muscle that appear to be 
responsible, at least in part, for the initial activation of 
mitochondrial biogenesis after exercise. These molecular 
signals include elevated levels of cytosolic Ca2+ (6,7), AMP 
(6), reactive oxygen species (ROS) (8) and possibly NAD+ 
(2) (Fig. 1). Increasing cytosolic Ca2+ levels in L6 muscle 
cells via caffeine treatment activates Ca2+-calmodulin 
kinase (CAMK) and increases markers of mitochondrial 
biogenesis, which include PGC-1a, Tfam, COX and citrate 
synthase (6,7); conversely, inhibitors of Ca2+ release abolish 
these caffeine effects (7). The activation of muscle AMPK 
by 5’aminoimidazole-4-carboxyamide-ribonucleoside 
(AICAR) in L6 muscle cells also increases many of these 
mitochondrial biogenesis markers (6). Increasing the ROS 
levels in skeletal muscle cells activates the redox sensitive 
kinases, AMPK and p38 MAPK, resulting in elevated PGC-
1a (8); these ROS effects are blocked by co-treatment with 
antioxidants (8).
Type 2 Diabetes 
Skeletal muscle accounts for approximately 80% of insulin-
stimulated glucose uptake and a key defect in the aetiology 
of type 2 diabetes (T2D) is the development of insulin 
resistance in skeletal muscle. It has been well documented 
that skeletal muscle of people with T2D have impaired 
mitochondrial function, due to reduced mitochondrial 
content (9). Furthermore, many of the regulatory components 
involved in mitochondrial biogenesis, such as PGC-1a and 
NRF-1, are also known to be reduced in the skeletal muscle 
of people with T2D (9). This led to the popular hypothesis 
that the reduction in mitochondrial content in T2D was 
causative in the development of insulin resistance in skeletal 
muscle, via the reduced capacity for lipid oxidation and 
subsequent accumulation of lipids that may impair insulin-
stimulated glucose uptake (10). However, it has been shown 
that the majority of studies who find reduced mitochondrial 
content in T2D are confounded by several factors, such as 
not controlling for reduced physical activity, which strongly 
impacts mitochondrial content (10). Therefore it appears 
that mitochondrial dysfunction, at least in humans with 
T2D, is secondary to the development of insulin resistance 
in skeletal muscle.
Although mitochondrial dysfunction may not be causative 
in the development of insulin resistance in skeletal muscle, 
it is still quite likely that improving skeletal muscle 
mitochondrial content and function could be causative in 
improving insulin resistance. Indeed, people with T2D 
respond to endurance training with normal increases 
in insulin sensitivity and skeletal muscle mitochondrial 
proteins (10). Furthermore, studies that mimic the exercise 
training response via electrotransfection of PGC-1a into 
rat skeletal muscle result in increased PGC-1a protein 
content, mtDNA and mitochondrial enzyme activities with 
concomitant improvements in insulin sensitivity in skeletal 
muscle (11).
Motor Neuron Disease: Amyotrophic Lateral Sclerosis 
Amyotrophic lateral sclerosis (ALS) is a severe motor 
neuron disorder resulting in the progressive degeneration of 
upper and lower motor neurons, a decline in strength, severe 
muscle atrophy and respiratory insufficiency. It is the most 
common of the five motor neuron diseases. There is no cure 
for ALS and death occurs within 3–5 years after diagnosis. 
The general consensus is that ALS is caused by motor neuron 
death and that perturbations in mitochondrial function are an 
important component in ALS pathogenesis. Skeletal muscle 
of ALS patients has considerable mitochondrial disruption 
and dysfunction, indicated by NADH:CoQ oxidoreductase 
and cytochrome c oxidase deficiency, reduced mtDNA and 
reduced levels of mitochondrial Mn-SOD (12). Neuronal 
degeneration in an animal model of ALS (transgenic mice 
expressing SOD1G93A) is preceded by the degeneration 
of the neuromuscular junction (13) and muscle atrophy 
and degeneration (14), suggesting that skeletal muscle 
degeneration may contribute to neurodegeneration and 
play a key role in the cause and/or progression of ALS. 
It is therefore logical to hypothesise that the pathogenesis 
and progression of ALS may involve perturbations in 
signalling molecules that are normally required for the 
healthy maintenance of mitochondrial biogenesis and 
function in skeletal muscle, as well as muscle mass overall. 
A significant reduction in PGC-1a and PGC-1β, as well as in 
key downstream targets such as ERRα, NRF-1, MFN1, Mfn2 
and COXIV, has been observed in ALS patients, suggesting 
that perturbations in these molecular signalling proteins 
may play a role in the onset or severity of the disease.
Ageing
In cells of individuals of advanced age, mitochondria 
often appear abnormally rounded. They tend to be lower in 
density and a reduced mtDNA content is evident. In ageing, 
there are reduced activities of some enzymes, impaired 
respiration and there is evidence of increased oxidative 
stress. It has been suggested that the increased production 
of reactive oxygen species is a key factor contributing to 
the perturbations in mitochondrial morphology and DNA 
content and that this is a major contributor to the aging 
process. Correlations between mtDNA mutations, impaired 
biogenetics and muscle wasting have been observed 
(15). From a molecular perspective, AMPK activation is 
reduced, as are levels of PGC-1a and Mfn2, while Fission 1 
(Fis1) is increased in muscle from the elderly. A reduction 
in these signalling molecules is consistent with impaired 
mitochondrial biogenesis and function, and would also 
contribute to the age-related decline in muscle mass. Several 
of these observations can be influenced by a reduction in 
physical activity; thus, when levels of such activity are 
considered, age-related impairment in mitochondrial 
activities is not present. Because exercise increases 
mitochondrial biogenesis and function in young and older 
subjects, the maintenance of physical activities throughout 
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Mitochondria and Muscle Wasting 
The complex and interconnected mitochondrial network 
involves the dynamic processes of mitochondria fission 
(division) and mitochondrial fusion (joining). The 
equilibrium between fission and fusion is responsible 
for the mitochondrial shape, size and networking within 
mitochondria. Major proteins regulating fission include 
dynamin related-protein 1 (Drp1) and Fis1, while 
fusion is controlled by Mfn1, Mfn2 and optic atrophy 
1 (Opa1). Mitochondrial fusion involves the fusion 
of both mitochondrial membranes and is required to 
maintain mitochondrial morphology and metabolism 
(2). Mitochondrial fusion is controlled by Mfn1 and Mfn2 
that are located on the outer mitochondrial membrane. 
Recent studies have shown that disruption of regulatory 
components of the mitochondrial network influences the 
balance of skeletal muscle atrophy programs. Deletion 
of both Mfn1 and Mfn2 in mouse skeletal muscle causes 
mitochondrial dysfunction, compensatory mitochondrial 
proliferation, mtDNA depletion, high levels of mtDNA 
mutations and muscle atrophy (16). Additionally, under 
catabolic conditions it was shown that mitochondria are 
removed via autophagy and that this was caused by the 
activation of AMPK and mitochondrial fission (2). The 
inhibition of fission abrogated muscle wasting under fasting 
conditions. PGC-1a and PGC-1b regulate Mfn1 and Mfn2 
in an ERRα-dependent manner in C2C12 myotubes (17). 
In mice the double deletion of skeletal muscle PGC-1a and 
PGC-1b results in a 60-70% reduction in Mfn1 and Mfn2 
mRNA levels and also induces mitochondrial dysfunction 
(18). Skeletal muscle wasting is also associated with an 
increase in the mitochondrial E3 ubiquitin-ligase 1 (Mul1). 
Mul1 is a FoxO-regulated gene that increases mitochondrial 
fission via the ubiquitination and degradation of Mfn2. The 
suppression of Mul1 protects against mitochondrial fission 
and was found to partially rescue muscle wasting (19). 
Nuclear factor 90 (NF90) is involved in transcription and 
translation. Mice transgenically overexpressing NF90 have 
skeletal muscle atrophy, with mitochondrial vacuolation 
caused by autophagocytosis (20). This was accompanied 
by reduced expression of PGC-1a, PGC-1β and NFR-1. 
Additionally, COX-4 and COX-2 mRNA levels were 
reduced. Whether NF90 acts as a direct transcriptional 
suppressor of PGC-1a/β remains to be established.
Conclusion
Mitochondria play a vital role in maintaining health 
over the lifespan of the organism. They regulate substrate 
utilisation, energy production and, consequently, muscle 
size and function. It is clear that perturbation in muscle 
mitochondrial biogenesis can significantly contribute to 
the onset and or severity of various chronic diseases and 
the numerous health issues our ageing population faces. 
Mitochondria display high sensitivity to contraction-
initiated signals and demonstrate rapid plasticity. Therefore, 
physical activity and exercise play important roles in 
promoting the biogenesis and function of these organelles 
and, as a consequence, maintains cellular and whole body 
health.
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